BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
26 juin 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies Healthcare Conference
31 mai 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
11 mai 2023 16h01 HE
|
BioAtla, Inc.
Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in...
BioAtla to Participate in the JMP Securities Life Sciences Conference
08 mai 2023 16h05 HE
|
BioAtla, Inc.
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
04 mai 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
23 mars 2023 16h05 HE
|
BioAtla, Inc.
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the...
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
16 mars 2023 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Change in Executive Leadership
27 févr. 2023 08h07 HE
|
BioAtla, Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
23 févr. 2023 08h00 HE
|
BioAtla, Inc.
Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate...
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
10 janv. 2023 08h00 HE
|
BioAtla, Inc.
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011...